The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.
Dobkin
Roseanne DeFronzo
RD
Department of Psychiatry, UMDNJ, Robert Wood Johnson Medical School, D317, 675 Hoes Lane, Piscataway, NJ 08854, USA. dobkinro@umdnj.edu
Menza
Matthew
M
Bienfait
Karina L
KL
Gara
Michael
M
Marin
Humberto
H
Mark
Margery H
MH
Dicke
Allison
A
Tröster
Alexander
A
D000328:Adult; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009661:Nortriptyline / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D017374:Paroxetine; D009661:Nortriptyline
J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):377-83
16963587
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
J Neurol Sci. 2006 Oct 25;248(1-2):131-7
16780884
Biol Psychiatry. 2005 Aug 1;58(3):204-10
16018984
Dement Geriatr Cogn Disord. 2005;20(2-3):140-4
16020942
Am J Psychiatry. 2000 Dec;157(12):1949-54
11097959
J Neurol Neurosurg Psychiatry. 1992 May;55(5):377-82
1602311
Am J Psychiatry. 1992 Apr;149(4):443-54
1372794
J Neurol Sci. 2006 Oct 25;248(1-2):151-7
16797028
Am J Geriatr Psychiatry. 2008 Sep;16(9):752-9
18697883
Psychol Med. 2004 Jan;34(1):125-36
14971633
Arch Neurol. 1995 Dec;52(12):1164-9
7492290
J Psychosom Res. 1998 Jul;45(1):5-13
9720850
Br J Med Psychol. 1959;32(1):50-5
13638508
Neurology. 2007 Jul 24;69(4):342-7
17581943
J Psychiatr Res. 2003 Mar-Apr;37(2):99-108
12842163
Eur J Neurol. 2005 Jan;12(1):9-15
15613141
Neurology. 2009 Mar 10;72(10):886-92
19092112
Mov Disord. 2009 Jul 15;24(9):1325-32
19412944
BMJ. 1993 May 29;306(6890):1437-40
8518639
J Am Geriatr Soc. 1997 Jul;45(7):844-9
9215336
Arch Neurol. 1996 Feb;53(2):175-9
8639068
Arch Clin Neuropsychol. 2007 Aug;22(6):711-8
17644304
Neurology. 1995 Apr;45(4):672-6
7723954
Arch Neurol. 1997 Aug;54(8):982-6
9267973
J Neuropsychiatry Clin Neurosci. 2002 Winter;14(1):31-6
11884652
Arch Neurol. 1992 Mar;49(3):305-7
1536634
Eur J Neurol. 1998 May;5(3):291-295
10210845
Neuropsychologia. 2007 Jun 18;45(11):2499-507
17507058
Adv Neurol. 1990;53:245-9
2239463
Int J Geriatr Psychiatry. 2003 Jul;18(7):571-6
12833300